Aktienanalyse zu Jasper Therapeutics Inc (JSPR)JSPRJasper Therapeutics Inc

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics targeting mast cell-driven diseases, such as Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU), and Asthma. Its lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (c-Kit) receptor on mast and stem cells. Briquilimab is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the c-Kit receptor, inhibiting signaling for mast cells and a maintenance signal for hematopoietic stem cells. KIT inhibition with briquilimab has demonstrated clinical outcomes both as a conditioning agent for stem cell transplant in SCID and Fanconi anemia. Its pipeline also includes KP-104 (vensobafusp alfa), a bifunctional complement inhibitor in clinical development, and KP-701, a preclinical B-cell receptor-targeted therapy. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Jasper Therapeutics Inc is a good buy right now, primarily due to its recent price increase of 18.93% yesterday and a significant reduction in net loss to $2.76 million in Q2 2026 from $26.72 million the previous year. The company is also advancing its clinical pipeline, with an end-of-Phase 2 meeting for KP-104 expected in the first half of 2027, which could drive future growth. However, the main risk is the current negative earnings per share (EPS) of -0.10 and the need for additional funding to support its clinical studies.